CHOP Researchers Develop Potentially Safer, More Effective Gene Therapy Vector for Blood Disorders
CHOP Researchers Develop Potentially Safer, More Effective Gene Therapy Vector for Blood Disorders --New preclinical study shows vector results in significantly more hemoglobin production than vectors currently used in gene therapy for sickle cell disease and beta-thalassemia-- News provided by Share this article Share this article PHILADELPHIA, Jan. 29, 2021 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) have developed a gene therapy vector for blood disorders like sickle cell disease and beta-thalassemia that is potentially safer and more effective than those cur...